Kayla Meyers

Document Type

Honors Thesis


A local delivery method of an injectable modified cellulose nanofiber hydrogel, DNCNF PAA 10%, loaded with the chemotherapy drug temozolomide, TMZ, was studied to investigate the most effective and safest therapy window on duke melanoma 6 (DM6) and human dermal fibroblast cells (HDF-α). Loaded hydrogel concentrations of 25μM1000μM were administered inside PDMS microcurrent device for 72 hours, removed, cells stained, and quantified. For the long-term study, treatment was administered for 72 hours, treatment removed, and cells recovered for 72 hours. The data was quantified using a fluorescent live/dead cell assay and cells counted. There was a cell death dosage effect seen after the 250μM TMZ hydrogel treatment as the concentrations increased. The 500μM TMZ hydrogel had ~7-14% DM6 viability with ~50% HDF-α viability. Dosages higher than the 500μM TMZ hydrogel treatment and free 500μM TMZ had nonspecific killing of both cell types. The long-term melanoma recovery study showed surviving melanoma have possible TMZ resistance. The most effective and safest therapy window was DNCNF PAA 10% 500μM-750μM TMZ. Currently, the treatment therapy window found is being studied further involving co-culturing of both cell types. Future studies recommended are TMZ resistance studies and in vivo animal studies.

Publication Date






To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.